Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: Biomarkers of systemic inflammation have been shown to predict outcomes in patients with cancer of unknown primary (CUP). We sought to validate these findings in patients with confirmed CUP (cCUP) and explore their role alongside existing clinicopathological prognostic categories.
PATIENTS AND METHODS: CUP oncologist from across the United Kingdom were invited to include patients with cCUP referred to their local CUP multidisciplinary team. Patient demographics, clinical, pathological and outcome data were recorded and analysed.
RESULTS: Data were available for 548 patients from four CUP services. 23% (n = 124) of patients met clinicopathological criteria for favourable-risk cCUP. On multivariate analysis c-reactive protein (CRP) (p < 0.001) and the Scottish Inflammatory Prognostic Score (SIPS: combining albumin and neutrophil count) (p < 0.001) were independently predictive of survival. CRP and SIPS effectively stratified survival in patients with both favourable-risk and poor-risk cCUP based on clinicopathological features.
CONCLUSIONS: Biomarkers of systemic inflammation are reliable prognostic factors in patients with cCUP, regardless of clinicopathological subgroup. We recommend that CRP or SIPS are incorporated into routine clinical assessments of patients with cCUP as a tool to aid investigation and/or treatment decision-making across all groups. Established clinicopathological factors can then be used to inform management pathways and specific systemic anticancer therapy selection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancer medicine - 13(2024), 3 vom: 26. Feb., Seite e6988 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Harvey, Svenja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 27.02.2024 Date Revised 29.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.6988 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36894090X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36894090X | ||
| 003 | DE-627 | ||
| 005 | 20240229235205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6988 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM36894090X | ||
| 035 | |a (NLM)38404120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Harvey, Svenja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2024 | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Biomarkers of systemic inflammation have been shown to predict outcomes in patients with cancer of unknown primary (CUP). We sought to validate these findings in patients with confirmed CUP (cCUP) and explore their role alongside existing clinicopathological prognostic categories | ||
| 520 | |a PATIENTS AND METHODS: CUP oncologist from across the United Kingdom were invited to include patients with cCUP referred to their local CUP multidisciplinary team. Patient demographics, clinical, pathological and outcome data were recorded and analysed | ||
| 520 | |a RESULTS: Data were available for 548 patients from four CUP services. 23% (n = 124) of patients met clinicopathological criteria for favourable-risk cCUP. On multivariate analysis c-reactive protein (CRP) (p < 0.001) and the Scottish Inflammatory Prognostic Score (SIPS: combining albumin and neutrophil count) (p < 0.001) were independently predictive of survival. CRP and SIPS effectively stratified survival in patients with both favourable-risk and poor-risk cCUP based on clinicopathological features | ||
| 520 | |a CONCLUSIONS: Biomarkers of systemic inflammation are reliable prognostic factors in patients with cCUP, regardless of clinicopathological subgroup. We recommend that CRP or SIPS are incorporated into routine clinical assessments of patients with cCUP as a tool to aid investigation and/or treatment decision-making across all groups. Established clinicopathological factors can then be used to inform management pathways and specific systemic anticancer therapy selection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Scottish inflammatory prognostic score | |
| 650 | 4 | |a c-reactive protein | |
| 650 | 4 | |a cancer of unknown primary | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a systemic anticancer therapy | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Stares, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Julie-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Thottiyil, Tharun Joseph Vattam |e verfasserin |4 aut | |
| 700 | 1 | |a Conway, Alicia-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Haigh, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Jackie |e verfasserin |4 aut | |
| 700 | 1 | |a Knowles, Gillian |e verfasserin |4 aut | |
| 700 | 1 | |a Dasgupta, Sonali |e verfasserin |4 aut | |
| 700 | 1 | |a Shiu, Kai-Keen |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Barrie, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Clive, Sally |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 13(2024), 3 vom: 26. Feb., Seite e6988 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3 |g day:26 |g month:02 |g pages:e6988 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6988 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 3 |b 26 |c 02 |h e6988 | ||